A Seeking Alpha analysis assigned Hims & Hers Health (HIMS) a "buy" rating. The analysis set a fair value estimate of $41 per share. The report suggests the market may overly discount the company due to regulatory uncertainties. The analysis points to the Novo partnership as a potential driver for significant subscriber growth, possibly over 50% annually.
The bullish case relies on conservative assumptions for the core business. These include a 17% compound annual revenue growth rate. It also assumes an 18% adjusted EBITDA margin by 2030. Key risks include undisclosed churn rates, ongoing margin compression, and an FTC complaint. Despite these risks, the report suggests substantial potential upside for the stock.